TransMedics Group, Inc. Stock News

TransMedics is expected to report disappointing Q4 results, with industry data suggesting it will likely miss and come in at the low end of guidance. The company's Q3 performance was poor, underperforming in Heart, Lung, and Liver transplants, leading to a significant loss of investor confidence. Despite a challenging Q4, early signs indicate a stronger start to 2025, potentially allowing manag...

SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2025 / A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v.

RADNOR, Pa., Feb. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against TransMedics Group, Inc. (“TransMedics”) (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities b...

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v.

NEW YORK , Feb. 24, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purch...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In TransMedics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-9...

TransMedics Group is revolutionizing organ transplant therapy with its FDA-approved Organ Care System, enhancing donor organ preservation and transport. Despite a Q3 earnings miss and short-seller allegations, TMDX has shown remarkable five-year growth and operational advantages. TMDX's market share in heart, liver, and lung transplants has significantly increased, with future plans for kidney ...

SAN FRANCISCO , Feb. 21, 2025 /PRNewswire/ -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v.